Klin Farmakol Farm. 2008;22(4):149-152

Contraindications in gynecological practice

Michael Fanta
Gynekologicko-porodnická klinika 1. LF UK a VFN v Praze

Review article presenting summary of contraceptive methods and modalities available in our market, their properties, contraindications, reliability and additional positive effects.

Keywords: Key words: ethinyl estradiol, progestins, contraindications.

Published: January 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Fanta M. Contraindications in gynecological practice. Klin Farmakol Farm. 2008;22(4):149-152.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Nelson A. Contraceptive Update Y2K: Need for Contraception and New Contraceptive Options. Clinical Cornerstone 2000, 3 (1): 48-62. Go to original source... Go to PubMed...
    2. Čepický P, Cibula D, Dvořák K, et al. Doporučení k předpisu kombinované hormonální antikoncepce. Česká gynekologie 2000, 65 (4), 279-282, aktualizace 2005. Go to PubMed...
    3. Medical eligibility for contraceptive use WHO 2004, www.who.int/reproductive-health.
    4. Čepický P, Cibula D, Dvořák K, et al. Doporučení k předpisu gestagenní kontracepce. Česká gynekologie 2001; 66: 140.
    5. Meade TW, Greenberg G, Thompson SG. Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 30-microgram oestrogen preparations. Br. Med. J. 1980; 280:1157-1161. Go to original source... Go to PubMed...
    6. Endrikat J, Muller U, Dusterberg B. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to efficacy, cycle control, and tolerance. Contraception 1997; 55: 131-137. Go to original source... Go to PubMed...
    7. Endrikat J, Dusterberg B, Ruebig A, Gerlinger C, Strowitzki T. Comparison of efficacy, cycle control, and tolerability of two lowdose oral contraceptives in a multicenter clinical study. Contraception 1999; 60: 269-274. Go to original source... Go to PubMed...
    8. Rosenberg MJ, Meyers A, Roy V. Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: a randomized trial of 20?g and 35?g estrogen preparations. Contraception 1999; 60: 321-329. Go to original source... Go to PubMed...
    9. Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am. J. Obstet. Gynecol. 1998; 179: 577-582. Go to original source... Go to PubMed...
    10. Thiboutot D, Archer DF, Lemay A, et al. A randomized, controlled trial of a low dose contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel in acne treatment. Fertil Steril 2001, 76 (3), 461-468. Go to original source... Go to PubMed...
    11. Gestodene Study Group 322. The safety and contraceptive efficacy of a 24-day low-dose OC regimen containing gestodene 60 ?g and ethinylestradiol 15 ?g. Eur. J. Contracept. Reprod. Health Care 1999; 4: 9-15. Go to original source... Go to PubMed...
    12. Gestodene Study Group 324. Cycle control, safety and efficacy of a 24-day regimen of gestodene 60 ?g/ethinylestradiol 15 ?g and a 21-day regimen of desogestrel 150 ?g/ethinylestradiol 20 ?g. Eur. J. Contracept. Reprod. Health Care 1999; 4: 17-25. Go to original source... Go to PubMed...
    13. Fanta M. Transdermální forma kombinované hormonální antikoncepce. Česká gynekologie 2003; 68 (5), 341-345. Go to PubMed...
    14. Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008; 371 (9609): 303-14. Go to original source... Go to PubMed...
    15. Hannaford PC. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioners' oral contraception study. BMJ 2007; 335: 651. Go to original source... Go to PubMed...
    16. Walsh JS, Eastell R, Peel NF. Effects of Depot medroxyprogesterone acetate on bone density and bone metabolism before and after peak bone mass: a case-control study. J Clin Endocrinol Metab. 2008 Apr; 93 (4): 1317-1323. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.